Emerging therapeutic strategies for CD30-positive lymphomas

Area of Science:

• Hematology
• Oncology
• Immunotherapy

Background:

• Brentuximab vedotin (BV) has improved outcomes in CD30-expressing lymphomas.
• The ECHELON-2 trial established BV plus cyclophosphamide, doxorubicin, and prednisone (CHP) as a frontline standard for systemic anaplastic large cell lymphoma, outperforming CHOP.
• Limitations of a universal BV+CHP approach are emerging as the therapeutic landscape diversifies.

Purpose of the Study:

• Critically evaluate the evidence supporting BV+CHP in CD30-positive lymphomas.
• Explore novel therapeutic strategies beyond the current standard of care.
• Discuss the potential for personalized, precision-driven treatment approaches.

Main Methods:

• Review of clinical trial data, focusing on the ECHELON-2 trial.
• Assessment of emerging therapies including immunotherapies, targeted agents, and cellular therapies.
• Analysis of treatment strategies for relapsed/refractory CD30-positive lymphomas.

Main Results:

• BV+CHP demonstrates superior survival in frontline systemic anaplastic large cell lymphoma compared to CHOP.
• Evidence suggests limitations to a universal BV+CHP standard, necessitating exploration of alternatives.
• Novel therapies, including anti-CD30 chimeric antigen receptor (CAR)-T cell therapy, show transformative potential for relapsed/refractory disease.

Conclusions:

• The treatment of CD30-positive lymphomas is shifting from a one-size-fits-all model to personalized strategies.
• Optimizing efficacy and minimizing toxicity are key goals in developing new treatment paradigms.
• Future directions involve integrating BV-based combinations, targeted agents, and advanced cellular therapies for improved patient outcomes and quality of life.